Exact Mass: 534.2736588
Exact Mass Matches: 534.2736588
Found 500 metabolites which its exact mass value is equals to given mass value 534.2736588
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Corchoroside A
Constituent of Corchorus olitorius (Jews mallow) and Hesperis matronalis (sweet rocket). Corchoroside A is found in tea, herbs and spices, and green vegetables. Helveticoside is found in herbs and spices. Helveticoside is a constituent of Hesperis matronalis (sweet rocket) D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins
GV 150013X
Corotoxigenin-3-o-alpha-L-rhamnopyranoside
Pyropheophorbide a
Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside]
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is found in fruits. 3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is a constituent of Cydonia oblonga (quince). Constituent of Cydonia oblonga (quince). 3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is found in fruits.
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside]
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside] is found in fruits. 7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside] is a constituent of leaves of quince (Cydonia vulgaris)
Pyrophaeophorbide a
Pyrophaeophorbide a is found in tea. Pyrophaeophorbide a is isolated from te Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
8-{2-Methyl-5-[2-oxo-2-(4-phenyl-piperazin-1-yl)-ethoxy]-2H-pyrazol-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
Daglutril
C31H38N2O6 (534.2729727999999)
Phytoporphyrin
Pyropheophorbide a
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))
C25H43O10P (534.2593707999999)
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)
C25H43O10P (534.2593707999999)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
9-hydroxy-9-[[(E)-2-(hydroxymethyl)-3-[3-(hydroxymethyl)-6-propan-2-ylcyclohex-2-en-1-yl]prop-2-enoyl]oxymethyl]-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid
N,N-bis[2-[(2-chlorobenzyl)-diethyl-ammonio]ethyl]oxalimidate
3beta-beta-D-Glucopyranosyloxy-15xi-hydroxy-5beta,14xi-carda-16,20(22)-dienolid|3beta-beta-D-glucopyranosyloxy-15xi-hydroxy-5beta,14xi-carda-16,20(22)-dienolide
(1R*,3S*,5S*,6aR*,7R*,8R*,9S*,10S*,10aR*)-1,10-bis(acetyloxy)-3,5,6,6a,7,8,9,10-octahydro-9-hydroxy-5-methoxy-7,8-dimethyl-7-[(2Z)-3-methylpenta-2,4-dien-1-yl]naphtho[1,8a-c]furan-3-yl butanoate
2beta,9-dihydroxymegastigma-4-en-3-one 9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
(13-hydroxyblumenol C) 9-O-beta-(6-O-rhamnosylglucoside)
Ajugamarin F4
3-O-beta-D-(6-O-linolenoyl)glucopyranosyl-gamma-pyranone
6alpha,18-diacetoxy-4alphahydroxy-19-tigloyloxy-neo-clerod-13-en-15,16-olide
Delta(16)-digitoxigenin beta-D-glucoside|Delta16-digitoxigenin beta-D-glucoside
(3beta,5alpha)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-14-hydroxy-11-oxocard-20(22)-enolide|11-oxouzarigenin 3-(alpha-L-rhamnopyranoside)
12alpha-Brom-3beta,13-dihydroxy-oleanan-28-saeure-13-lacton|12alpha-bromo-3beta,13-dihydroxy-oleanan-28-oic acid-13-lactone|12alpha-bromo-3beta,13beta-dihydroxyolean-28-oic acid gamma-lactone|12alpha-bromo-3beta-hydroxy-oleanan-13beta,28-olide
2??-Acetoxy-4??-hydroxy-6??-p-hydroxybenzoyloxy-10??-benzoyloxy-dauc-8-ene
[1,3-diacetyloxy-9,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-enyl)-1,3,5,6,6a,8,9,10-octahydrobenzo[d][2]benzofuran-5-yl] 2-methylbutanoate
C29H42O9_9-Hydroxy-9-[({(2E)-2-(hydroxymethyl)-3-[3-(hydroxymethyl)-6-isopropyl-2-cyclohexen-1-yl]-2-propenoyl}oxy)methyl]-6-isopropyl-1-oxo-1,3,5a,6,7,8,9,9a-octahydro-2-benzoxepine-4-carboxylic acid
C29H42O9_Carda-5,20(22)-dienolide, 3-(beta-D-glucopyranosyloxy)-14-hydroxy-, (3beta,9xi)
SB236057A
CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8057; ORIGINAL_PRECURSOR_SCAN_NO 8055 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8094; ORIGINAL_PRECURSOR_SCAN_NO 8093 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8100; ORIGINAL_PRECURSOR_SCAN_NO 8098 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8129; ORIGINAL_PRECURSOR_SCAN_NO 8126 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8145; ORIGINAL_PRECURSOR_SCAN_NO 8143 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8145; ORIGINAL_PRECURSOR_SCAN_NO 8144
9-hydroxy-9-[[(E)-2-(hydroxymethyl)-3-[3-(hydroxymethyl)-6-propan-2-ylcyclohex-2-en-1-yl]prop-2-enoyl]oxymethyl]-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid_major
9-hydroxy-9-[[(E)-2-(hydroxymethyl)-3-[3-(hydroxymethyl)-6-propan-2-ylcyclohex-2-en-1-yl]prop-2-enoyl]oxymethyl]-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid_21.8\\%
Ala Lys Met Trp
Ala Lys Trp Met
Ala Met Lys Trp
Ala Met Trp Lys
Ala Trp Lys Met
Ala Trp Met Lys
Cys Glu Lys Arg
Cys Glu Arg Lys
Cys Lys Glu Arg
Cys Lys Arg Glu
Cys Lys Val Trp
Cys Lys Trp Val
Cys Arg Glu Lys
Cys Arg Lys Glu
Cys Arg Arg Thr
Cys Arg Thr Arg
Cys Thr Arg Arg
Cys Val Lys Trp
Cys Val Trp Lys
Cys Trp Lys Val
Cys Trp Val Lys
Glu Cys Lys Arg
Glu Cys Arg Lys
Glu His His Ile
Glu His His Leu
Glu His Ile His
Glu His Leu His
Glu Ile His His
Glu Lys Cys Arg
Glu Lys Lys Met
Glu Lys Met Lys
Glu Lys Arg Cys
Glu Leu His His
Glu Met Lys Lys
Glu Arg Cys Lys
Glu Arg Lys Cys
Phe Ile Gln Gln
Phe Leu Gln Gln
Phe Asn Arg Val
Phe Asn Val Arg
Phe Gln Ile Gln
Phe Gln Leu Gln
Phe Gln Gln Ile
Phe Gln Gln Leu
Phe Arg Asn Val
Phe Arg Val Asn
Phe Val Asn Arg
Phe Val Arg Asn
His Glu His Ile
His Glu His Leu
His Glu Ile His
His Glu Leu His
His His Glu Ile
His His Glu Leu
His His Ile Glu
His His Lys Asn
His His Leu Glu
His His Asn Lys
His Ile Glu His
His Ile His Glu
His Lys His Asn
His Lys Asn His
His Leu Glu His
His Leu His Glu
His Asn His Lys
His Asn Lys His
Ile Glu His His
Ile Phe Gln Gln
Ile His Glu His
Ile His His Glu
Ile Gln Phe Gln
Ile Gln Gln Phe
Lys Ala Met Trp
Lys Ala Trp Met
Lys Cys Glu Arg
Lys Cys Arg Glu
Lys Cys Val Trp
Lys Cys Trp Val
Lys Glu Cys Arg
Lys Glu Lys Met
Lys Glu Met Lys
Lys Glu Arg Cys
Lys His His Asn
Lys His Asn His
Lys Lys Glu Met
Lys Lys Met Glu
Lys Met Ala Trp
Lys Met Glu Lys
Lys Met Lys Glu
Lys Met Trp Ala
Lys Asn His His
Lys Pro Gln Tyr
Lys Pro Tyr Gln
Lys Gln Pro Tyr
Lys Gln Tyr Pro
Lys Arg Cys Glu
Lys Arg Glu Cys
Lys Thr Thr Trp
Lys Thr Trp Thr
Lys Val Cys Trp
Lys Val Trp Cys
Lys Trp Ala Met
Lys Trp Cys Val
Lys Trp Met Ala
Lys Trp Thr Thr
Lys Trp Val Cys
Lys Tyr Pro Gln
Lys Tyr Gln Pro
Leu Glu His His
Leu Phe Gln Gln
Leu His Glu His
Leu His His Glu
Leu Gln Phe Gln
Leu Gln Gln Phe
Met Ala Lys Trp
Met Ala Trp Lys
Met Glu Lys Lys
Met Lys Ala Trp
Met Lys Glu Lys
Met Lys Lys Glu
Met Lys Trp Ala
Met Gln Arg Thr
Met Gln Thr Arg
Met Arg Gln Thr
Met Arg Thr Gln
Met Thr Gln Arg
Met Thr Arg Gln
Met Trp Ala Lys
Met Trp Lys Ala
Asn Phe Arg Val
Asn Phe Val Arg
Asn His His Lys
Asn His Lys His
Asn Lys His His
Asn Arg Phe Val
Asn Arg Val Phe
Asn Val Phe Arg
Asn Val Arg Phe
Pro Lys Gln Tyr
Pro Lys Tyr Gln
Pro Gln Lys Tyr
Pro Gln Tyr Lys
Pro Tyr Lys Gln
Pro Tyr Gln Lys
Gln Phe Ile Gln
Gln Phe Leu Gln
Gln Phe Gln Ile
Gln Phe Gln Leu
Gln Ile Phe Gln
Gln Ile Gln Phe
Gln Lys Pro Tyr
Gln Lys Tyr Pro
Gln Leu Phe Gln
Gln Leu Gln Phe
Gln Met Arg Thr
Gln Met Thr Arg
Gln Pro Lys Tyr
Gln Pro Tyr Lys
Gln Gln Phe Ile
Gln Gln Phe Leu
Gln Gln Ile Phe
Gln Gln Leu Phe
Gln Arg Met Thr
Gln Arg Thr Met
Gln Thr Met Arg
Gln Thr Arg Met
Gln Tyr Lys Pro
Gln Tyr Pro Lys
Arg Cys Glu Lys
Arg Cys Lys Glu
Arg Cys Arg Thr
Arg Cys Thr Arg
Arg Glu Cys Lys
Arg Glu Lys Cys
Arg Phe Asn Val
Arg Phe Val Asn
Arg Lys Cys Glu
Arg Lys Glu Cys
Arg Met Gln Thr
Arg Met Thr Gln
Arg Asn Phe Val
Arg Asn Val Phe
Arg Gln Met Thr
Arg Gln Thr Met
Arg Arg Cys Thr
Arg Arg Thr Cys
Arg Ser Ser Trp
Arg Ser Trp Ser
Arg Thr Cys Arg
Arg Thr Met Gln
Arg Thr Gln Met
Arg Thr Arg Cys
Arg Val Phe Asn
Arg Val Asn Phe
Arg Trp Ser Ser
Ser Arg Ser Trp
Ser Arg Trp Ser
Ser Ser Arg Trp
Ser Ser Trp Arg
Ser Trp Arg Ser
Ser Trp Ser Arg
Thr Cys Arg Arg
Thr Lys Thr Trp
Thr Lys Trp Thr
Thr Met Gln Arg
Thr Met Arg Gln
Thr Gln Met Arg
Thr Gln Arg Met
Thr Arg Cys Arg
Thr Arg Met Gln
Thr Arg Gln Met
Thr Arg Arg Cys
Thr Thr Lys Trp
Thr Thr Trp Lys
Thr Trp Lys Thr
Thr Trp Thr Lys
Val Cys Lys Trp
Val Cys Trp Lys
Val Phe Asn Arg
Val Phe Arg Asn
Val Lys Cys Trp
Val Lys Trp Cys
Val Asn Phe Arg
Val Asn Arg Phe
Val Arg Phe Asn
Val Arg Asn Phe
Val Trp Cys Lys
Val Trp Lys Cys
Trp Ala Lys Met
Trp Ala Met Lys
Trp Cys Lys Val
Trp Cys Val Lys
Trp Lys Ala Met
Trp Lys Cys Val
Trp Lys Met Ala
Trp Lys Thr Thr
Trp Lys Val Cys
Trp Met Ala Lys
Trp Met Lys Ala
Trp Arg Ser Ser
Trp Ser Arg Ser
Trp Ser Ser Arg
Trp Thr Lys Thr
Trp Thr Thr Lys
Trp Val Cys Lys
Trp Val Lys Cys
Tyr Lys Pro Gln
Tyr Lys Gln Pro
Tyr Pro Lys Gln
Tyr Pro Gln Lys
Tyr Gln Lys Pro
Tyr Gln Pro Lys
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside]
Erizimin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
3-Higgp
9-[2-(Butoxycarbonyl)phenyl]-6-(diethylamino)-N,N-diethyl-3H-xant hen-3-iminium chloride
2-hydroxyethyl 2-methylprop-2-enoate,2-methylidenehexanoic acid,methyl 2-methylprop-2-enoate,prop-2-enoic acid,styrene
Daglutril
C31H38N2O6 (534.2729727999999)
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-
C31H38N2O6 (534.2729727999999)
1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea
(1-Ethyl-6,7-dihydro-5H-spiro(furo(2,3-f)indole-3,4-piperidin)-5-yl)(2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl)methanone
alleoside a
A cardenolide glycoside that consists of strophanthidin having a digitoxosyl group attached at position 3. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins
3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
longirostrerone D
A natural product found in Chaetomium longirostre. An azaphilone that is 6H-furo[2,3-h]isochromene-6,8(6aH)-dione substituted by a 4-hydroxy-2-methyl-6-oxocyclohexyl group at position 3, a methyl group at position 6a, and a 4,6,8-trimethyldeca-2,4-dienoyl group at position 9. Isolated from Chaetomium longirostre, it exhibits cytotoxic activities.
Eurysterol B
An organic sodium salt that is monosodium salt of eurysterol B sulfonic acid. Isolated from an undescribed marine sponge of the genus Euryspongia collected in Palau, it is cytotoxic and exhibits antifungal activity against both amphotericin B-resistant and wild-type strains of Candida albicans.
sodium(E)-((1R,4aS,4bS,8aS,10aS)-1-(2-((2S,5R)-2,5-dimethoxy-2,5-dihydrofuran-3-yl)ethyl)-4b,8,8,10a-tetramethyldecahydrophenanthren-2(1H,3H,4bH)-ylidene)methyl sulfate
A natural product found in Coscinoderma species.
caseamemebrol B
A diterpenoid of the clerodane group isolated from the leaves and twigs of Casearia membranacea. It exhibits significant cytotoxicity against human prostrate (PC-3) cancer cells.
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-[[(2R,3S)-8-(2-benzofuranyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-cyclohexyl-1-methylurea
[1,3-Diacetyloxy-9,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-enyl)-1,3,5,6,6a,8,9,10-octahydrobenzo[d][2]benzofuran-5-yl] 2-methylbutanoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C25H43O10P (534.2593707999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C25H43O10P (534.2593707999999)
Pyrophaeophorbide a
Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
Corchoroside A
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside]
(1s,2r,6s,7r,9r,11r,12r,13s,15s,16r)-15-[(1r)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-6,12,15-trihydroxy-13-methoxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecan-3-one
(1r,3as,3bs,5ar,7s,9ar,9br,11ar)-3a-hydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde
4-[(1s,3r,5s,7r,9s,10s,12r,14r,15s,18r,19r,22s,23r)-9,10,22-trihydroxy-14-(hydroxymethyl)-7,18-dimethyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosan-19-yl]-5h-furan-2-one
(2r,3r,4s,6r,7r,8s,11s)-4,6-bis(acetyloxy)-14-[(2s)-1-methoxy-1-oxopropan-2-yl]-3,7,11-trimethyl-15-oxatricyclo[9.3.1.0²,⁷]pentadeca-1(14),12-dien-8-yl butanoate
3-amino-2-hydroxy-n-[(6s,7r)-7,10,10-trimethyl-12-(2-methylpropyl)-2,5,9,11-tetraoxo-3-(sec-butyl)-1,4,8-trioxacyclododecan-6-yl]benzenecarboximidic acid
(1r,3as,5as,7r,9as,11ar)-7-{[(2r,5s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
2-[8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl 2-methylbutanoate
n-[7-(butanoyloxy)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
(1r,3s,5r,6ar,7s,8s,10r,10ar)-1,3-bis(acetyloxy)-10-hydroxy-7-[(2r)-2-hydroxy-3-methylidenepent-4-en-1-yl]-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl 2-methylbutanoate
4-[(3as,3br,5ar,7r,9as,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one
(4s)-4-[(3r)-3-{[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}butyl]-3,5,5-trimethylcyclohex-2-en-1-one
1,14,15-trihydroxy-17-[1-hydroxy-1-(4-methyl-5-oxo-2h-furan-2-yl)propan-2-yl]-9,9,18-trimethyl-4,8-dioxapentacyclo[11.7.0.0³,⁷.0³,¹⁰.0¹⁴,¹⁸]icosan-5-one
4-(3-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}butyl)-3,5,5-trimethylcyclohex-2-en-1-one
(4s)-4-hydroxy-3,5,5-trimethyl-4-[(3r)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one
(5as,6r,9s,9as)-9-{[(4as,5r,8s,8ar)-8-(hydroxymethyl)-5-isopropyl-4a,5,6,7,8,8a-hexahydro-2h-chromene-3-carbonyloxy]methyl}-9-hydroxy-6-isopropyl-1-oxo-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid
(1s,2r,5r,7s,9r,11r,12r,14s,15r,16s)-15-[(1s)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-12,14,15-trihydroxy-5-methoxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecan-3-one
(1r,3s,5s,6ar,7s,8s,10r,10ar)-1,3-bis(acetyloxy)-10-hydroxy-7-[(2r)-2-hydroxy-3-methylidenepent-4-en-1-yl]-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2r)-2-methylbutanoate
(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,4s,5r,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
(6as)-3-[(1s,2s,4r)-4-hydroxy-2-methyl-6-oxocyclohexyl]-6a-methyl-9-[(2e)-4,6,8-trimethyldeca-2,4-dienoyl]furo[2,3-h]isochromene-6,8-dione
2,3-dihydro-3β-methoxyixocarpalactone b
{"Ingredient_id": "HBIN003990","Ingredient_name": "2,3-dihydro-3\u03b2-methoxyixocarpalactone b","Alias": "NA","Ingredient_formula": "C29H42O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5671","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
ajugamarin f4
{"Ingredient_id": "HBIN014979","Ingredient_name": "ajugamarin f4","Alias": "NA","Ingredient_formula": "C29H42O9","Ingredient_Smile": "CCC(C)C(=O)OC(CC1(C(CC(C2(C1CCCC23CO3)COC(=O)C)OC(=O)C)C)C)C4=CC(=O)OC4","Ingredient_weight": "534.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14209","TCMID_id": "805","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "102004689","DrugBank_id": "NA"}